Diabetes mellitus (DM), an increasingly prevalent chronic metabolic disease, is characterised by prolonged hyperglycaemia, which leads to long-term health consequences. Although much effort has been put into understanding the pathogenesis o
A team of scientists at the Massachusetts Institute of Technology (MIT), Brigham and Women’s Hospital, and Harvard University have developed a noninvasive alternative—an oral capsule containing a tiny vibrating motor that is designed to stimulate the stomach to produce the same sense of fullness people experience after eating a large meal.
Giving high-risk patients access to an obesity specialist through their regular primary care clinic increased their chances of receiving at least one evidence-based weight-management treatment, and led to more weight lost in just a year, a new University of Michigan study finds.
Researchers will delve into emerging research in diabetes, obesity, reproductive health and other aspects of hormone health during the Endocrine Society’s ENDO 2024 news conferences June 1-4.
Researchers at the Icahn School of Medicine at Mount Sinai have designed a regenerative medicine therapy to speed up diabetic wound repair. Using tiny fat particles loaded with genetic instructions to calm down inflammation, the treatment was shown to target problem-causing cells and reduce swelling and harmful molecules in mouse models of damaged skin. Details on their findings were published in the May 20 online issue of the Proceedings of the National Academy of Sciences (PNAS).
The sweet taste receptor, expressed in taste bud cells, conveys sweetness from the mouth when it is activated. Monell researchers delved into how the sweet-taste receptor might be the first stop in a metabolic surveillance system for sugar. They team found that stimulation and inhibition of the receptor demonstrates that it helps regulate glucose metabolism in humans and may have implications for managing such metabolic disorders as diabetes.
The Endocrine Society is delighted to announce that Lily Ng, PhD, and Douglas Forrest, Ph.D., have won the Society's 2024 Endocrine Images Art Competition for their image of the astrocyte cell that expresses type 2 deiodinase.
The joint guideline is designed to help clinicians manage patients who have, or are at risk of developing, glucocorticoid-induced adrenal insufficiency. At least 1% of the global population uses chronic glucocorticoid therapy as anti-inflammatory or immune-suppressive agents.
Fu-Shin Yu, Ph.D., professor of ophthalmology, visual and anatomical sciences in the Wayne State University School of Medicine, received an award from the National Eye Institute of the National Institutes of Health for his study aiming to reverse the adverse effects of diabetes on eyesight.
Researchers at Wake Forest University School of Medicine have been approved for a $1 million award by the Patient-Centered Outcomes Research Institute (PCORI) for a methodology study.
Scientists at Johns Hopkins Medicine say that an experimental monoclonal antibody drug called mAb43 appears to prevent and reverse the onset of clinical type 1 diabetes in mice, and in some cases, to lengthen the animals’ lifespan.
A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death.
The Endocrine Society has appointed Zane B. Andrews, Ph.D., of Monash University in Melbourne, Australia, as Editor-in-Chief of its flagship basic science journal, Endocrinology.
Learn how ancestry changes genetic risk variants’ impact on type 2 diabetes in childhood cancer survivors & alkylating agent exposure magnifies diabetes risk.
An intricate simulation performed by UT Southwestern Medical Center researchers using one of the world’s most powerful supercomputers sheds new light on how proteins called SNAREs cause biological membranes to fuse.
New research by scientists at University of California San Diego has shown that cells regulate cAMP/PKA signaling by forming liquid droplets that segregate excess PKA catalytic subunits where they can do no harm. Some cancers may block the formation of liquid droplets, leading to hyperactive signaling and tumor formation.
Mitchell A. Lazar, M.D., Ph.D., the Rhoda and Willard Ware Professor in Diabetes and Metabolic Disease, and Director of the Institute for Diabetes, Obesity, and Metabolism in the Perelman School of Medicine at the University of Pennsylvania, is the 2025 recipient of the George M. Kober Medal from the Association of American Physicians (AAP). Lazar will receive the honor in Chicago at the AAP’s annual meeting which takes place April 25-27, 2025.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
